Anmeldung erfolgt in Kürze...
Details werden geladen...
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data | The Manila Times
- Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant -
Ähnliche Seiten
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/fennec-pharmaceuticals-announces-new-research-supporting-integration-and-use-of-pedmark-at-the-2026-asco-annual-meeting/2349737Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting/2349722Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa/2346165Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/moleculin-highlights-abstract-accepted-for-poster-presentation-at-the-2026-asco-annual-meeting-highlighting-cardiac-safety-data-for-annamycin/2349702Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | The Manila Times
https://www.manilatimes.net/2026/05/17/tmt-newswire/globenewswire/nanobiotix-announces-presentation-of-part-1-data-from-a-randomized-phase-2-clinical-trial-evaluating-jnj-1900-nbtxr3-in-stage-3-inoperable-lung-cancer/2345706